Overview
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Eligibility
Inclusion Criteria:
- Have been diagnosed with plaque psoriasis by a dermatologist
- Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
- Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes
Exclusion Criteria:
- Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
- Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history


